Do viral load and CD8 cell count at initiation of tritherapy influence the increase of CD4 T-cell count?

AIDS

Volumn 12, Issue 15, 1998, Pages

  Keita Perse, Olivia ^a   Roger, Pierre Marie ^a   Pradier, Christian ^a   Pugliese, Pascal ^a   Cottalorda, Jacqueline ^a   Dellamonica, Pierre ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

CD4 T cells; HIV; Prognosis; Tritherapy; Viral load

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; PROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; COMPUTER PROGRAM; COMPUTER SYSTEM; DATA ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE REGRESSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; T LYMPHOCYTE; VIRUS LOAD;

EID: 0032558740     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199815000-00002     Document Type: Article

References (16)

1. Mellors JW, Rinaldo Jr CR, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
2. + lymphocytes as prognosis markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
3. + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997, 126:929-938.
4. Dormont J: Stratégies d'utilisation des antirétroviraux dans l'infection par le VIH, 1997. Recommandations des groupes d'experts cliniciens et virologues, Medecine-Sciences Flammarion.
5. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeters or less. N Engl J Med 1997, 337:725-733.
6. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
7. Fauci AS: Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993, 262:1011-1018.
8. Fauci AS, Pantaleo G, Stanley S, Weissman D: Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996, 124:654-663.
9. Schnittman SM, Fox L: Preliminary evidence for partial restoration of immune function in HIV 1 infection with potent antiretroviral therapies: clues from the fourth conference on retroviruses and opportunistic diseases. AIDS Res Human Retrovir 1997, 13:815-818.
10. Foster S, Beverley P, Aspinall R: gp120-induced programmed cell death in recently activated T cells without subsequent ligation of the T cell receptor. Eur J Immunol 1995, 25:1770-1782.
11. + T lymphocytes from activation-induced apoptosis triggered by HIV-1: implications for pathogenesis and therapy. AIDS 1995, 9:35-42.
12. Wood R, Montoya JG, Kundu SK, Schwartz DH, Merigan TC: Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J Infect Dis 1993, 167:519-525.
13. Davey Jr RT, Chaitt DG, Piscitelli SC: Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 1997, 175:781-789.
14. Sneller MC: Consensus symposium on combined antiviral therapy; an overview of interferon and IL-2 combinations for the treatment of HIV infection. Antiviral Res 1996, 29:105-109.
15. Kovacs JA, Baseler M, Dewar RJ, et al.: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995, 332:567-575.
16. Kinter A, Fauci AS. Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement. Immunol Res 1996, 15:1-15.